fbpx
Influenza

Location: Cleveland, OH; Jackson, TN; Orlando, FL

Indication: Influenza

Sponsor: Emergo Therapeutics, Inc.

PI: Hassan Alzoubi, MD; Melanie Hoppers, MD; Christopher Chappel, MD

Ages: 18-64

Criteria:

  • Fever
  • Flu-like symptoms
    • Cough, sore throat, or stuffy nose
    • Headache, body aches, chills or fatigue

Compensation: You may be compensated for your time and participation

About:

  • Participate in a 4-week study
  • Receive clinic visits and study drugs at no cost to you
  • No insurance required

This is a Phase 2b, multi-center, double-blind, randomized, placebo-controlled, parallel-group study of NKT versus placebo in otherwise healthy adults presenting with acute uncomplicated ILI due to influenza or other respiratory viruses in a community setting.

Influenza

Therapeutic Area: Influenza

Location:  Cleveland, OH; Jackson, TN; Orlando, FL

Sponsor: Genentech, Inc.

PI: Hassan Alzoubi, MD; Melanie Hoppers, MD; Christopher Chappel, MD

Intervention/Treatment: Baloxavir marboxil or placebo

Phase: 3B

Ages: 5-64

Criteria:

  • Have influenza symptom onset within 48 hours
    • Fever, cough, sore throat, nasal congestion, headache, feverishness or chills, muscle or joint pain, fatigue)
  • Diagnosed with acute influenza infection by the investigator

Compensation: You may be compensated for your time and participation

About: Otherwise healthy index patients (IP) are randomized to either baloxavir marboxil or placebo if their influenza symptoms onset was within 48 hours of screening. Their households are enrolled within 24 hours of randomization if at least 2 household contacts (HHC) have not received influenza vaccine within 6 months of screening and if all HHC screen negative for influenza infection. The main endpoints are assessed based on multiple respiratory swabs, obtained from both IP and HHC up to 9 (+/-1) days post IP randomization, and through the assessment of symptoms.

Start typing and press Enter to search